Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiovascular and Renal Risk Stratification in Patients Referred to an Onconephrology Clinic and Undergoing Different Oncology Therapies: A Real-World Study.

Biomedicines·2026
Same author

Risk stratification and relapse pattern in triple-negative breast cancer with pathological complete response after neoadjuvant treatment: the European GAMBIT real-world study.

Nature communications·2026
Same author

Evaluation of Drug-Drug Interactions Using Drug-PIN® in Patients Receiving Avelumab Maintenance for Advanced Urothelial Carcinoma: Evidence from the MALVA Study (Meet-URO 25).

Oncology and therapy·2026
Same author

Gut microbiome dysbiosis and cancer: A systematic review on the emerging role of probiotics in oncology.

Critical reviews in oncology/hematology·2026
Same author

Real-world effectiveness of CDK4/6 inhibitors in older patients with HR+/HER2- advanced breast cancer: a sub-analysis of the multicenter, PALMARES-2 study.

Breast (Edinburgh, Scotland)·2026
Same author

Comparative real-world progression free survival of CDK4/6 inhibitors in HR+/HER2- breast cancer patients with bone metastases.

The oncologist·2026

Related Experiment Video

Updated: Jul 20, 2025

Author Spotlight: Emerging Technologies and Advanced Tools for Decoding Metabolomics Data Analysis
07:11

Author Spotlight: Emerging Technologies and Advanced Tools for Decoding Metabolomics Data Analysis

Published on: November 10, 2023

2.4K

Network approach in liquidomics landscape.

Daniele Santini1, Andrea Botticelli1, Antonio Galvano2

  • 1Oncologia Medica A, Policlinico Umberto 1, La Sapienza Università Di Roma, Rome, Italy.

Journal of Experimental & Clinical Cancer Research : CR
|August 4, 2023
PubMed
Summary

Liquid biopsy offers a less invasive alternative to tissue biopsy for cancer molecular profiling. This approach shows promise in cancer screening, diagnosis, and treatment selection, despite current standardization challenges.

Keywords:
CTCLiquid biopsyLiquidomicsMRDTargeted therapyctDNA

More Related Videos

A Strategy for Sensitive, Large Scale Quantitative Metabolomics
14:18

A Strategy for Sensitive, Large Scale Quantitative Metabolomics

Published on: May 27, 2014

21.0K
Deep Proteome Profiling by Isobaric Labeling, Extensive Liquid Chromatography, Mass Spectrometry, and Software-assisted Quantification
10:37

Deep Proteome Profiling by Isobaric Labeling, Extensive Liquid Chromatography, Mass Spectrometry, and Software-assisted Quantification

Published on: November 15, 2017

12.0K

Related Experiment Videos

Last Updated: Jul 20, 2025

Author Spotlight: Emerging Technologies and Advanced Tools for Decoding Metabolomics Data Analysis
07:11

Author Spotlight: Emerging Technologies and Advanced Tools for Decoding Metabolomics Data Analysis

Published on: November 10, 2023

2.4K
A Strategy for Sensitive, Large Scale Quantitative Metabolomics
14:18

A Strategy for Sensitive, Large Scale Quantitative Metabolomics

Published on: May 27, 2014

21.0K
Deep Proteome Profiling by Isobaric Labeling, Extensive Liquid Chromatography, Mass Spectrometry, and Software-assisted Quantification
10:37

Deep Proteome Profiling by Isobaric Labeling, Extensive Liquid Chromatography, Mass Spectrometry, and Software-assisted Quantification

Published on: November 15, 2017

12.0K

Area of Science:

  • Oncology
  • Molecular Diagnostics
  • Genomics

Background:

  • Tissue biopsy is invasive and has limitations for frequent cancer molecular profiling.
  • Cancer's evolving genomic profile necessitates less invasive and more accurate diagnostic alternatives.
  • Liquid biopsy, analyzing circulating tumor cells and nucleic acids in body fluids, emerges as a promising alternative.

Purpose of the Study:

  • To review the current knowledge on the limitations and strengths of various liquid biopsy forms.
  • To discuss the inclusion of liquid biopsy in routine cancer management.
  • To highlight novel biomarkers and future implications of liquid biopsy in oncology.

Main Methods:

  • Review of existing literature on liquid biopsy techniques and applications.
  • Analysis of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) in body fluids.
  • Exploration of biomarkers for treatment response and disease monitoring.

Main Results:

  • Liquid biopsy demonstrates promising results in cancer screening, diagnosis, prognosis, and recurrence risk assessment.
  • Identifies predictive biomarkers for treatment response (e.g., EGFR, KRAS mutations, MSI/MMR).
  • Enables prediction of minimal residual disease and recurrence risk through longitudinal ctDNA monitoring.

Conclusions:

  • Liquid biopsy is a rapidly advancing field with significant potential in clinical oncology.
  • Standardization of workflows is crucial for reproducibility and widespread clinical adoption.
  • Liquid biopsy offers a less invasive and more accessible approach to tumor molecular profiling for personalized cancer care.